



Media Statement

23 December 2004

CSL LIMITED AND NATIONAL BLOOD AUTHORITY SIGN NEW PLASMA PRODUCTS AGREEMENT

CSL Limited announced today that it has signed an agreement with the National Blood Authority, acting on behalf of both State and Commonwealth Governments, to continue to provide the Australian community with safe, secure and affordable plasma therapeutic products.

"CSL welcomes the opportunity to continue to provide life-saving plasma therapeutics to Australians living with a variety of serious medical conditions" the Managing Director and Chief Executive Officer of CSL Limited, Dr. Brian McNamee said today.

Under the new Plasma Products Agreement, CSL will supply a broad range of plasma therapeutics manufactured exclusively at its Broadmeadows, Victoria production facility from plasma provided by the Australian Red Cross Blood Service. In addition, under the new Agreement, CSL will provide a comprehensive range of services to the National Blood Authority and medical providers involved in specialised therapeutic areas.

The Agreement also supports the important, long standing collaboration between CSL and the Australian Red Cross Blood Service. This collaboration ensures that Australians will continue to have secure, safe and prompt access to a comprehensive range of plasma-derived medical treatments.

The Plasma Products Agreement will commence on 1 January 2005 and will run for five years until 31 December 2009.

For further information please contact:

Investors

Mr Mark Dehring
Head of Investor Relations
CSL Limited
Mobile: 0423 780 328

Media

Ms Rachel David
Director of Public Affairs
CSL Limited
Mobile: 0401 775 779

or

Hintons

Tim Duncan
Telephone: +61 3 9600 1979
Mobile: 0408 441 122